Channel 1 ESMO Colloquium

ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?

Date
23.09.2020
Time
13:00 - 14:30
Room
Channel 1
Chairs
  • Myung-Ju Ahn (Seoul, Korea, Republic of)
  • Martin Reck (Grosshansdorf, Germany)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Is Osimertinib the best single agent if 1st line?

Lecture Time
13:00 - 13:15
Speakers
  • Myung-Ju Ahn (Seoul, Korea, Republic of)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Should chemotherapy be combined upfront with EGFR TKI?

Lecture Time
13:15 - 13:30
Speakers
  • Ross Soo (Singapore, Singapore)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Is a combination of anti-angiogenic with EFGR TKI a new standard

Lecture Time
13:30 - 13:45
Speakers
  • Martin Reck (Grosshansdorf, Germany)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Do immune check point work in EGFR TKI?

Lecture Time
13:45 - 14:00
Speakers
  • Edward B. Garon (Santa Monica, CA, United States of America)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

In a multiline setting, what is the best sequencing?

Lecture Time
14:00 - 14:10
Speakers
  • Enriqueta Felip (Barcelona, Spain)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Conclusions

Lecture Time
14:10 - 14:15
Speakers
  • Myung-Ju Ahn (Seoul, Korea, Republic of)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents? ESMO Colloquium

Live Q&A

Lecture Time
14:15 - 14:30
Speakers
  • Myung-Ju Ahn (Seoul, Korea, Republic of)
  • Martin Reck (Grosshansdorf, Germany)
Session Name
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
Room
Channel 1
Date
23.09.2020
Time
13:00 - 14:30